CN113116908A

CN113116908A - Application of compound and composition thereof in preparing medicine for improving lung repair activity

Info

Publication number: CN113116908A
Application number: CN201911390892.XA
Authority: CN
Inventors: 林咏翔
Original assignee: BAIYUETE BIOTECHNOLOGY (SHANGHAI) CO LTD
Current assignee: BAIYUETE BIOTECHNOLOGY (SHANGHAI) CO LTD
Priority date: 2019-12-30
Filing date: 2019-12-30
Publication date: 2021-07-16

Abstract

The invention relates to a new application of a compound, in particular to an application of a compound and a composition thereof in preparing a medicine for improving lung repair activity. The present invention provides the use of a composition for enhancing pulmonary repair activity, wherein the composition is selected from the group consisting of: chlorogenic acid, beta-androgenic acid, any combination thereof and a pharmaceutically acceptable carrier. The invention also provides application of chlorogenic acid or beta-androgen in preparing medicaments for improving lung repair activity.

Description

Application of compound and composition thereof in preparing medicine for improving lung repair activity

Technical Field

The invention relates to a new application of a compound, in particular to an application of a compound and a composition thereof in preparing a medicine for improving lung repair activity.

Background

The lungs are the respiratory and filtering organs. The lungs normally secrete mucus to form a protective layer that prevents airborne pathogens (e.g., viruses, bacteria, fungi) or aerosols from attaching to the lungs. However, the lung has a limited ability to remove foreign substances, and some foreign substances may penetrate the protective layer to infect or damage the lung, thereby causing inflammation of the lung. In addition, pulmonary contusion, sepsis, hemorrhagic shock, etc. can cause severe pulmonary inflammation. A variety of immune cells (e.g., macrophages, neutrophils) involved in inflammatory reactions and stimulated and secreted proinflammatory cytokines (e.g., interleukin, tumor necrosis factor-alpha (TNF-alpha)) may cause lung re-injury, including alveolar damage, increased microvascular permeability, microthrombus, and in severe cases, even pulmonary edema, acute respiratory distress, etc. The aforementioned factors causing lung tissue damage may cause idiopathic pulmonary fibrosis (idiopathic pulmonary fibrosis) along with inflammatory reactions, symptoms including dry cough and progressive dyspnea, and may eventually lead to respiratory failure and death.

To maintain the normal function of the lung, the exposure to air pollutants and pathogens should be minimized to avoid lung cell inflammation, lung tissue damage and pulmonary fibrosis. Possible methods include avoiding smoking, wearing a mask, using an air purification device. In addition, if lung tissue damage has already developed, drugs that promote wound healing or inhibit inflammation should be administered. However, there are limited drugs known to be effective in promoting pulmonary repair activity, and these drugs are not necessarily capable of promoting pulmonary repair activity. Therefore, there is a need to develop a novel pharmaceutical product that can effectively improve lung repair activity.

Disclosure of Invention

In view of the above, the present invention provides a use of a composition for preparing a medicament for enhancing lung repair activity, wherein the composition comprises an effective concentration of a compound selected from the group consisting of: chlorogenic acid (Chlorogenic acid), beta-Arbitin (beta-Arbitin), any combination thereof, and a pharmaceutically acceptable carrier.

In one embodiment of the invention, the effective concentration of the compound is at least 20 μ g/mL.

Another objective of the present invention is to provide a use of Chlorogenic acid (Chlorogenic acid) for preparing a medicament for enhancing lung repair activity.

In one embodiment of the invention, the effective concentration of chlorogenic acid is at least 20 μ g/mL.

Another object of the present invention is to provide a use of β -androgenic acid (β -Arbitin) for preparing a medicament for enhancing lung repair activity.

In one embodiment of the invention, the effective concentration of beta-androgenic agent is at least 20 μ g/mL.

In one embodiment of the invention, the enhancing lung repair activity includes promoting wound repair of a lung epithelial cell.

In one embodiment of the present invention, the pharmaceutical is in the form of powder, granule, solution, colloid, or paste.

In summary, the compounds of the present invention have the following effects: can promote the growth of lung epithelial cells and the wound repair force to achieve the effect of improving the lung repair activity.

The following examples are presented to illustrate the present invention and are not to be construed as limiting the scope of the invention, which is intended to be limited only by the appended claims.

Drawings

FIG. 1 is an HPLC fingerprint of green pear young fruit extract;

figure 2 is a graph of data showing the effect of compounds TCI-PN-01 and TCI-PN-02 on promoting pulmonary repair activity, where p is <0.01 as compared to control; p <0.001, compared to control.

Detailed Description

Definition of

As used herein, the numerical values are approximations and all numerical data are reported to be within the 20 percent range, preferably within the 10 percent range, and most preferably within the 5 percent range.

According to the present invention, statistical analysis was performed using Excel software. Data are presented as mean ± Standard Deviation (SD), and differences between individual data are analyzed by student's t-test (student's t-test).

According to the invention, Chlorogenic acid (Chlorogenic acid), herein designated TCI-PN-01, has the following formula (I):

according to the invention, beta-androgenic acid (beta-Arbitin), herein designated TCI-PN-02, has the following formula (II):

in accordance with the present invention, the pharmaceutical may be manufactured in a dosage form (dosage form) suitable for parenteral (parenteral) or oral (oral) administration using techniques well known to those skilled in the art, including, but not limited to: injections (injections) [ for example, sterile aqueous solution (sterile aqueous solution) or dispersion (dispersion) ], sterile powder (sterile powder), troche (tablet), tablet (troche), buccal tablet (dosage), pill (pill), capsule (capsule), dispersible powder (dispersible powder) or granule (granule), solution, suspension (suspension), emulsion (emulsion), syrup (syrup), elixir (elixir), syrup (syrup), and the like.

The medicament according to the invention may be administered by a parenteral route (parenteral routes) selected from the group consisting of: intraperitoneal injection (intraperitoneal injection), subcutaneous injection (subcutaneous injection), intramuscular injection (intramuscular injection), and intravenous injection (intravenous injection).

The pharmaceutical according to the present invention may comprise a pharmaceutically acceptable carrier which is widely used in pharmaceutical manufacturing technology. For example, the pharmaceutically acceptable carrier may comprise one or more agents selected from the group consisting of: solvents (solvents), emulsifiers (emulsifiers), suspending agents (suspending agents), disintegrating agents (disintegrants), binding agents (binders), excipients (excipients), stabilizing agents (stabilizing agents), chelating agents (chelating agents), diluents (diluents), gelling agents (gelling agents), preservatives (preserving), lubricants (lubricants), absorption delaying agents (absorbing agents), liposomes (lipids), and the like. The selection and amounts of such agents are within the skill and routine skill of those skilled in the art.

According to the present invention, the pharmaceutically acceptable carrier comprises a solvent selected from the group consisting of: water, normal saline (normal saline), Phosphate Buffered Saline (PBS), sugar-containing solutions, aqueous alcohol-containing solutions (aqueous solution stabilizing alcohol), and combinations thereof.

Example 1 purification of Compounds TCI-PN-01 and TCI-PN-02

The compound purified in this example is obtained from green pear young fruit (green pear juice), and its variety may be sydney (p.nivalis), pyrus betulaefolia (p.bretschneideri), pyrus betulaefolia (p.lindleyi revir), or pyrus ussuriensis (p.pyrifolia Nakai), but is not limited thereto, and sydney, pyrus betulaefolia, or pyrus betulaefolia is preferred.

As used herein, the term "green pear young fruit (green pear fruit)" means the green pear fruit that comes within 90 days after flowering in Sydney, Duck pear, bird pear, or Traverse pear, preferably within 30-90 days.

Pears are a generic term for plants of the genus Pyrus (Pyrus), usually a deciduous tree or shrub, and a very few species are evergreen, belonging to the family Malus domestica, the family Rosaceae, the order Rosales. The leaves are oval in shape, and the sizes vary according to the species. The flower is white, or yellowish, pink, and has five petals. The fruit is round in shape, and has a thinner base and a thicker tail, which is commonly called as pear shape; the color of the peel of different varieties is very different, and the peel of different varieties has yellow, green, yellow-medium green, green-medium yellow, yellow-brown, green-brown, red-brown and brown, and the peel of individual variety also has mauve; the diameter of the wild pears is smaller and ranges from 1 cm to 4 cm, while the diameter of artificially cultivated varieties can reach 8 cm, and the length can reach 18 cm.

The pear fruit is usually eaten, has delicious taste and much juice, is sour in sweetness, is rich in nutrition, contains various vitamins and cellulose, and has completely different taste and texture of different kinds of pears. The pear can be eaten either raw or after being steamed. In terms of medical efficacy, the pears can relieve constipation and promote digestion, and are also beneficial to heart vessels. The heated pear juice contains a large amount of anticancer polyphenol, and the pear can be used for appreciation besides being eaten as a fruit.

In an embodiment of the present invention, the whole green pear young fruit is washed, and the whole green pear young fruit after washing is taken as an extraction solvent of water, alcohol or a mixture of alcohol and water, wherein the extraction solvent is preferably water, and the weight ratio of the extraction solvent to the green pear young fruit is in a range of 10-20: 1-5, homogenizing, and extracting in an extraction solvent at 50-100 ℃ for 0.5-3 hours. After extraction, it was cooled to room temperature, and the crude extract was filtered through a 400 mesh (mesh) sieve to obtain a filtrate. Finally, the filtrate is concentrated under reduced pressure at 45-70 ℃ to obtain a green pear young fruit extract, and the High Performance Liquid Chromatography (HPLC) fingerprint of the green pear young fruit extract is shown in figure 1.

Then, 10L of the extract of young green pear fruit was extracted by liquid-liquid phase partition using ethyl acetate and n-butanol solvents to obtain 12.1g of Ethyl Acetate Fraction (EAF) (5.8%), 37.1g of n-butanol fraction (BUF) (17.8%), and 158.9g of Water Fraction (WF) (76.4%).

Then, according to the biological activity guided separation method, the n-butanol soluble fraction of the green pear young fruit extract was purified with pure water, 50% methanol aqueous solution, and 100% methanol as eluents, and macroporous resin chromatography (column chromatography) method (column chromatography) using Dianion HP-20 (packing materials including Sephadex LH-20(Pharmacia, Piscataway, NJ, USA), Diaion HP-20(Mitsubishi Chemical Co., Japan), Merck Kieselgel 60(Art.9385), and Merck

RP-18(40 to 63 μm) (art.0250)) to obtain 3 fractions (BUF1 to BUF 3).

Then, the separated part of BUF1 was subjected to Medium Pressure Liquid Chromatography (MPLC) (MPLC)

Rf +, Teledyne ISCO, Lincoln, NE) with a linear gradient from pure water (0 min) to 100% methanol (50 min), and detectingThe wavelength was measured at 280nm to obtain 3 secondary fractions (BUF1-1 to BUF 1-3). Then, the High Performance Liquid Chromatography (HPLC) is performed by a BUF1-1 separation part through a reverse phase high performance liquid chromatography (pump system: Hitachi L-2310 series pump; detector: Hitachi L-2420UV-VIS detector, detection wavelength is 200-380 nm; data processing software: D-2000Elite software; analytical column: Mightysil RP-18GP 250(Kanto,250x 4.6mm,5 μm); semi-preparative column:

HS C₁₈(SUPELCO,250X 10.0mm,5 μm); preparing a grade pipe column:

HS C₁₈(SUPELCO,250 × 21.0mm,5 μm)) was purified (methanol/water-1/9), whereby compound TCI-PN-02 was obtained.

Further, the separated fraction of BUF2 was subjected to medium-pressure liquid chromatography (

Rf +, Teledyne ISCO, Lincoln, NE), with a linear gradient from pure water (0 min) to 100% methanol (80 min), and a detection wavelength of 280nm, to obtain 8 secondary fractions (BUF2-1 to BUF 2-8). Then, the compound TCI-PN-01 was purified by reverse phase high performance liquid chromatography using BUF2-4 separation units (methanol/water 3/7).

Then, TCI-PN-01 was subjected to hydrogen-nuclear magnetic resonance spectroscopy (¹H-NMR) (1D vs 2D spectra using 400MHz Varian 400 FT-NMR; chemical shift (chemical shift) is expressed in δ in ppm; tetramethylsilane (TMS; δ ═ 0) was used as an internal standard, coupling constants (J) were in Hz, and s window peak (singlet), d doublet (doubtet), t triplet (triplet), q quartet (quartet), p quintet, m multiplet, brs broad) and electrospray ionization mass spectrometry (ESIMS) (tandem mass spectrometry-two-dimensional ion trap tandem fourier transform mass spectrometry and ESI-MS/MS: the chemical structure was analyzed using a Bruker amaZon SL system and Thermo Orbitrap Elite system in m/z)Then, the Chlorogenic acid (Chlorogenetic acid) is confirmed to have the structural formula of the formula (I).

TCI-PN-02 warp¹After analyzing the chemical structure by H-NMR and ESIMS, the compound is confirmed to be beta-androsterone (beta-Arbitin) with the structural formula (II). Each of the above compounds is also commercially available from SIGMA.

FIG. 1 is an HPLC fingerprint of an extract of young green pear fruit using methanol (A) and water (B) as solvents, and additionally 0.1% formic acid at a flow rate of 1 mL/min under the extraction conditions: at 0 min, a: B is 2: 98; at 10 minutes, A: B is 2: 98; at 40 minutes, A: B is 70: 30; at 50 minutes, A: B is 100: 0; at 60 minutes, a: B is 100: 0. As a result of quantitative analysis, it was found that TCI-PN-01 was the most abundant compound and contained 1358 ppm.

Example 2 evaluation of the effectiveness of Compounds TCI-PN-01 and TCI-PN-02 in promoting Lung repair Activity

This example uses the human normal lung epithelial cell line BEAS-2b (ATCC CRL-9609) purchased from American Type Culture Collection (ATCC). The cells were cultured in bronchial epithelium basal medium (Lonza)^TMA Bronchial epithelial cell basal medium; thermo Fisher Scientific), BEBM medium for short.

In order to investigate whether compounds TCI-PN-01 and TCI-PN-02 affect the wound repair capacity of lung tissues, the present example uses a microscope to observe the change of wound healing status of the cell monolayer of human lung epithelial cell strain BEAS-2b treated with compounds TCI-PN-01 or TCI-PN-02. Briefly, cells were plated at 1.5X 10⁵The cells/well were seeded in 24-well plates (GeneDireX) containing BEBM medium and cultured overnight at 37 ℃ to form a cell monolayer. Thereafter, a wound was formed in the cell monolayer, the medium was removed and the cells were washed with PBS solution (Gibco). After that, BEAS-2b cells were divided into 4 groups including 2 experimental groups (i.e., experimental group 1 and experimental group 2), 1 EGF group and 1 control group. 2. mu.g/mL of Epidermal Growth Factor (EGF) (purchased from Gibco) was added to the cells of the EGF group, 20. mu.g/mL of the compound TCI-PN-01 was added to the cells of the experimental group 1, and 20. mu.g/mL of the compound TCI-PN-02 was added to the cells of the experimental group 2, as to the cells of the control groupOnly BEBM medium was added. Cell monolayers (triplicate experiments) were observed and photographed with a microscope (ZEISS) after wound formation (0 hours) and after incubation at 37 ℃ for 16 hours. The results of this example are shown in FIG. 2 and Table 1.

FIG. 2 is a graph of data on the utility of compounds TCI-PN-01 and TCI-PN-02 in enhancing pulmonary repair activity. As can be seen from fig. 2, the wound healing capacity of the experimental group 1 and the experimental group 2 was significantly increased compared to the control group and the EGF group. Compared with a control group, the relative multiple of the wound healing capacity of the experimental group 1 is improved by 5.42 times, and the relative multiple of the wound healing capacity of the experimental group 2 is improved by 3.05 times. Table 1 shows the quantitative data of the efficacy of TCI-PN-01 and TCI-PN-02 in promoting the growth of epithelial cells in the human lung.

TABLE 1

The results of this example show that compounds TCI-PN-01 and TCI-PN-02 can promote the growth of human lung epithelial cells, and achieve the effect of improving lung repair activity.

In conclusion, the compounds TCI-PN-01 and TCI-PN-02 of the invention can achieve the effect of improving the lung repair activity by promoting the wound repair capacity of lung epithelial cells.

Claims

1. Use of a composition for the manufacture of a medicament for enhancing lung repair activity, wherein the composition comprises an effective concentration of a compound selected from the group consisting of: chlorogenic acid, beta-androgenic acid, any combination thereof and a pharmaceutically acceptable carrier.

2. Use according to claim 1, wherein the improvement in lung repair activity comprises promoting wound repair of lung epithelial cells.

3. The use according to claim 1, wherein the effective concentration of the compound is at least 20 μ g/mL.

4. The use according to claim 1, wherein said medicament is in the form of a powder, granules, solution, gel, or paste.

5. Application of chlorogenic acid in preparing medicinal products for improving lung repairing activity is provided.

6. The use of claim 5, wherein promoting pulmonary repair activity comprises promoting wound repair of a lung epithelial cell.

7. Use according to claim 5, wherein the effective concentration of chlorogenic acid is at least 20 μ g/mL.

8. Application of beta-androgenic fruit extract in preparing medicine for improving lung repairing activity is disclosed.

9. The use of claim 8, wherein promoting pulmonary repair activity comprises promoting wound repair of a lung epithelial cell.

10. The use of claim 8, wherein the effective concentration of β -androgenic is at least 20 μ g/mL.